Share this PR

Press Contact

Mr Rohan

Marketsandmarkets

Contact Email

Social Media

Oligonucleotide Synthesis Market - Forecasts to 2021

PressReleasePing - July 11, 2017 -The report "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, Custom, Predesigned, Reagent Equipment), Application (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, Biotechnology) - Forecasts to 2021" ,The global oligonucleotide synthesis market is expected to reach USD 2.20 Billion by 2021 from USD 1.33 Billion in 2016, at a CAGR of 10.6% during the forecast period. Browse 229 market data tables and 53 figures spread through 248 pages and in-depth TOC on “Oligonucleotide Synthesis Market “ http://www.marketsandmarkets.com/Market-Reports/oligonucleotide-synthesis-market-200829350.html Early buyers will receive 10% customization on this reports The growth of this market is mainly driven by factors such as increasing R&D expenditure in pharmaceutical and biotechnology companies, increased use in clinical applications and molecular diagnostics, increasing government investments for the development of genomics, and evolving significance of RNA-interference oligos in therapeutics and diagnostics are key factors driving market growth for oligonucleotide synthesis. The report segments the oligonucleotide synthesis market based on product and services, applications, end user, and region. On the basis of products and services, the oligonucleotide synthesis market is segmented into synthesized oligonucleotides, reagents, and equipment. Synthesized oligonucleotides are expected to account for the largest share of oligonucleotide synthesis market, in 2016. The growth of the synthesized oligonucleotides segment is attributed to the increasing number of applications of synthesized oligonucleotides in research, diagnostics, and therapeutics. The rising demand for custom oligos also contributes to the growth of the synthesized oligonucleotides market. On the basis of application the oligonucleotide synthesis market is further segmented into research, diagnostic and therapeutics. Research segment is expected to account for the largest share of oligonucleotide synthesis market in 2016. Diagnostic segment is expected to grow at the highest CAGR during the forecast period. The growth of this segment is mainly attributed to the emerging application of molecular diagnostics (MDx) and genetic testing. The increasing use of technologies such as DNA microarrays in the analysis of biological samples and developing molecular oncology diagnostics tests also contribute in the growth of molecular diagnostics market. On the basis of end-user the oligonucleotide synthesis market is categorized into academic research institutes, diagnostic laboratories, pharmaceutical and biotechnology companies, and other end users (private research institutes and hospitals). In 2016, the academic research institutes segment is expected to be the major end-user segment in the oligonucleotide synthesis market. Academic researchers primarily use oligonucleotides for various applications in genetic engineering, polymerase chain reaction (PCR) activities, and high-throughput sequencing. The Sample Report For This Report@ http://www.marketsandmarkets.com/requestsample.asp?id=200829350 The oligonucleotide synthesis market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. North America is expected to account for the largest share of this market in 2016. However, the Asia-Pacific market is expected to grow at the highest CAGR, mainly due to the growing availability of synthesized oligos, along with an increase in R&D funding and activities in the APAC region. Furthermore, the increasing focus of prominent players on APAC is another factor driving the growth of this market. The oligonucleotide synthesis market is a highly fragmented market, with several big and emerging players. Key market players include Bioautomation Corporation (U.S.), L.G.C Biosearch Technologies, Inc. (U.S.), Eurofins Genomics (Germany), Eurogentec S.A (Belgium), GE Healthcare (U.S.), Integrated DNA Technologies (IDT) (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies (U.S.), Nitto Denko Avecia Inc. (U.S.). Get The PDF Brochure For This Report@ http://www.marketsandmarkets.com/pdfdownload.asp?id=200829350 About MarketsandMarkets™: MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. Contact: Mr. Rohan MarketsandMarkets™ 701 Pike Street Suite 2175, Seattle, WA 98101, United States Tel: 1-888-600-6441


Creative Commons License

This press release is licensed under a Creative Commons Attribution 3.0 Unported License.